MIRA PHARMACEUTICALS, INC. COMMON STOCK

NASDAQ: MIRA (MIRA Pharmaceuticals, Inc.)

Last update: yesterday, 9:55AM

0.660

0.01 (1.77%)

Previous Close 0.648
Volume 90,523
Price / Book 3.34
52 Weeks Range
0.510 (-22%) — 1.69 (156%)
Diluted EPS (TTM) -0.470
Total Debt/Equity (MRQ) 0.04%
Current Ratio (MRQ) 12.85
Operating Cash Flow (TTM) -6.14 M
Levered Free Cash Flow (TTM) -3.26 M
Return on Assets (TTM) -193.30%
Return on Equity (TTM) -355.82%

AIStockmoo Score

1.3
Value 30% 0.0
AI Insight info NA
Relative Valuation info NA
Financial Health info 0.0
Timing 30% 2.8
AI Technical info NA
Technical Oscillators info 3.0
Technical Moving Averages info 2.5
Candle Patterns info NA
Sentiment 20% 0.0
Analyst Consensus info 0.0
News Mood info NA
Smart Money 20% 0.8
Insider Activity info NA
Institutional Flow info 2.1
Short Interest info -2.2
Environment ×1.00
Macro Environment info -1.3
Sector vs Market (6M) +10.3%
Pillar Agreement ×1.25
Not in score
Price Volatility info 1.4
Final Score 1.26

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Mixed Bullish
Drug Manufacturers - General (Global) Mixed Bullish
Stock MIRA Pharmaceuticals, Inc. Mixed Mixed

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
MIRA - - - 3.34
SNY - 5.01% - 1.40
GILD - 1.93% - 16.00
AMGN - 2.14% - 17.60
GRFS - 1.07% - 0.900
BIIB - - - 1.94

Select this tab to load the latest available analysis.

Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.

Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Small Growth
% Held by Insiders 19.68%
% Held by Institutions 5.60%

Ownership

Name Date Shares Held
Cross Staff Investments Inc 30 Sep 2026 359,401
First American Bank 30 Sep 2026 60,000

No data within this time range.

Institutions

Institutional ownership: 7.43%

Positions Holders Shares
Increased 8 673,009
Decreased 12 102,950
New 2 20,841
Sold out 6 37,839

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 282,319 1.4
15 Oct 2026 349,714 2.4
30 Sep 2026 408,844 2.4
15 Sep 2026 447,832 1.0
31 Aug 2026 205,296 4.1
14 Aug 2026 211,083 1.5

FINRA short interest via Nasdaq, reported twice a month.

Date Type Details
29 Oct 2026 Yahoo Finance Inside Deep Principle: The AI That Runs Its Own Chemistry Experiments to Discover New Materials
HANGZHOU, CHINA / ACCESS Newswire / October 29, 2026 / Inside a lab in Hangzhou, an AI system named Mira recently pushed a single-step reaction's selectivity from 51.82% to 85% in three months, without a chemist manually running the experiments.
29 Oct 2026 Yahoo Finance MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide
SKNY-1's Weight Reduction Without Significant Changes in Food Consumption Suggests a Potential Role for Energy Expenditure, Contrasting With Semaglutide's Initial Food-Intake Suppression and Significant Post-Treatment Increase MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc.…
22 Oct 2026 Yahoo Finance MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
Positive IND-Enabling Proof-of-Concept Study Demonstrates Sustained Efficacy Without Observed Tolerance, Reduced Inflammation-Associated Swelling, and Favorable TolerabilityMIAMI, Oct. 22, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage…
21 Oct 2026 Yahoo Finance Modera Launches AI-Powered Platform Mira to Support Tailored Financial Advice for Clients
Modera Wealth Management, LLC ("Modera"), a fee-only wealth management firm serving individuals, families, business owners, and nonprofit organizations, today announced it has launched Mira, a proprietary agentic AI-powered platform. Mira is designed to harmonize data and support tailored financial…
17 Sep 2026 Yahoo Finance MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
Protocol Submitted for IRB Review at a Leading Cancer Research Institution, Advancing the Study Toward Site InitiationMIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral…
16 Sep 2026 Yahoo Finance Copper Giant Identifies Thirteen Targets Beyond the Mocoa Resource and Its Interpreted Extensions
Copper Giant Resources Corp. ("Copper Giant" or the "Company") (TSXV: CGNT) (OTCQX: CGNRF) (FRA: 29H0) today reports the results of an independent geophysical modelling and predictive targeting study completed by Mira Geoscience Ltd. ("Mira") over its Mocoa copper-molybdenum porphyry project in…
01 Sep 2026 Yahoo Finance Landmark 2026 Clinical Study Validates At-Home Quantitative Multi-Hormone Monitoring Against Ultrasound Gold Standard
A landmark clinical study published in Reproductive BioMedicine Online (Bouchard et al., 2026) provides strong diagnostic accuracy validation for at-home quantitative multi-hormone tracking, establishing a major milestone in reproductive healthcare and FemTech.
01 Sep 2026 Yahoo Finance MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
Positive Toxicology Results From 7-Day Rat and Dog Studies Characterize Tolerability and Inform Dose Selection for Next Phase of IND-Enabling Program, Targeting Q1 2027 IND SubmissionMIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a…

Recent Signals candle patterns and EMA crosses

▲ Bullish EMA cross Last session · 13 Nov
Short term · EMA 7/20
The 7-day EMA crossed above the 20-day: short-term momentum turned up.

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria